Syntara Limited (SNT) Earnings Call Transcript & Summary

Good morning, and welcome to a General Meeting of Syntara Limited, which has been called by Notice of Meeting dated 17 January 2025. We have a quorum, and I now declare the meeting open. My name is Cameron Billingsley, the Company Secretary of Syntara. Today's meeting is being held as a virtual meeting via live webcast with the use of the Zoom platform and also the Lumi platform for voting. Shareholders and proxies have the ability to ask questions via the Zoom platform and to submit votes via the Lumi meeting platform. You need to be logged on to both platforms if you wish to both participate and vote. Firstly, let me briefly introduce our Board, Dr. Kathleen Metters, Non-Executive Chair.

Good morning, everybody.

Mr. Gary Phillips, our CEO.

Good morning.

Dr. Simon Green, Non-Executive Director.

Hello, everyone.

Hashan De Silva, Non-Executive Director.

Good morning.

I'd also like to introduce our CFO, Tim Luscombe.

Good morning.

With this meeting, we'll take the notice of meeting as read and -- but we will also display them as the meeting progresses. [Operator Instructions] Please note that while we can submit questions from now on, we will address them at the relevant times in the meeting, which will be after proposing each item of business and just before we go into the formal part of the business. [Operator Instructions] Voting today will be conducted by way of a poll on all items of business using the Lumi meeting platform. Voting is now open for all resolutions. If you are eligible to vote at this meeting, a polling icon has or will shortly appear in the Lumi meeting platform. You have the ability to change your vote up until the time we declare voting closed, which will be towards the end of the meeting. We've received a couple of questions in advance of the meeting. So before we move into the formal part of the meeting, I'd just like to hand over to Gary, the CEO of the company, to answer the questions that have been received. Gary, would you like to answer those questions, please?

Thanks, Cameron. Yes, as Cameron says, these questions aren't to do with the resolutions before us, but they were -- we received them earlier, and I thought it was worth sharing them before we start the meeting. So the first one was, will the market be updated in March with the myelofibrosis SNT-5505 interim data? And I guess the answer to that is we will have more data from the study as we go through March. Our timetable is that we hope to present our data into a package of information to the FDA in quarter 2, probably April. That data -- there is the intention to release that data to the market. But obviously, it depends on whether we have any questions or we think that the data we've received is in any way still needs further work before we release it. But yes, certainly, the plan is that we would update the market around that March, April time frame. The second question was what's been the delay with the skin scarring development program. And I think we said that we would update the market in quarter 4, and we have rolled over into another quarter. We are working obviously with an external group here, Professor Fiona Wood's group in Perth. And those discussions are going well, and we will be making an update to the market in this quarter as well as other information on the skin scarring trials that are underway at the moment. So you can expect to hear something from us quite shortly. And then finally, how has the recent interest from big pharma been? I guess that's referring to the myelofibrosis data that we put out in December. So we have had a number of meetings with pharma companies, both at the American Society of Hematology in December when we were there presenting our information and also -- so there is a big meeting at the beginning of the year called JPMorgan. It's held over in the U.S. in San Francisco, and that's a meeting where many of the big companies go and you can get invitations to meet. And I met with many of the main players in the myelofibrosis and hematology market while I was there earlier in January. So yes, there have been quite a bit of interest in the data we put out and certainly a lot of interest in seeing the data that comes when we have patients that have crossed the 12-month mark in the study. So yes, it's been -- I think I've been pleased with the level of interest here. So with that, that was the questions we received beforehand. And now I'll hand over to the Chair of the company, Kathleen Metters, to take us through the rest of the meeting.

Thank you, Gary, and good morning again, everybody. So the purpose of the meeting today is to obtain shareholder approval for a number of resolutions for our recently announced Tranche 2 placement for participation by a fund associated with one of our directors to acquire shares in Tranche 2, to approve the grant of the option fees to our corporate advisers and to refresh the company's capacity to issue shares under ASX Listing Rule 7.1 by ratifying the previous issue of securities under Tranche 1. We will proceed with the formal items of business. Resolution 1. Resolution 1 is an ordinary resolution that relates to the approval of the issue of shares under the second tranche of the placement that we announced in December 2024. Voting exclusions apply with respect to resolution 1. The proxy votes received prior to the meeting are set out online. Does anyone have any questions in relation to resolution 1?

Kathleen, I'm not showing any questions.

Thank you. Resolution 2. Resolution 2 is an ordinary resolution that seeks approval for the KP Rx Healthcare Trust or its nominee and associate of our Director, Mr. Hashan De Silva, to precipitate in the second tranche of the placement. Voting exclusions apply with respect to resolution 2. The proxy votes received prior to the meeting are set out online. Does anyone have any questions in relation to resolution 2?

Kathleen, I'm not seeing any questions showing.

Thank you. Resolution 3. Resolution 3 is an ordinary resolution that relates to the approval of the grant of option fees to the corporate advisers for the provision of corporate advisory services to the company. Voting exclusions apply with respect to resolution 3. The proxy votes received prior to the meeting are set out online. Does anyone have any questions in relation to resolution 3?

Kathleen, I'm not seeing any questions showing.

And finally, Resolution 4. Resolution 4 is an ordinary resolution that relates to the ratification of the issue of shares under the first tranche placement that we announced in December 2024 in order to refresh the company's 15% capacity. Voting exclusions apply in respect to resolution 4. The proxy votes received prior to the meeting are set out online. Are there any questions in relation to resolution 4?

I think I'm not seeing any questions.

That concludes our discussion on the items of business. I am about to close the voting system. Please ensure that you have cast your vote on all resolutions. I will pause briefly to allow you time to finalize those votes. [Voting]

Voting is now closed. The results of these votes will be released to the stock exchange later today. As there is no further business, I declare the meeting closed, and thank you for attending.